Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma： a Single-arm, Single-centre, Open-label Trial

NCT05786989 is registered in ClinicalTrials.gov with Chongqing University Cancer Hospital as lead sponsor.

NCT NCT05786989
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05786989 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma： a Single-arm, Single-centre, Open-label Trial
Lead sponsor
Chongqing University Cancer Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
February 28, 2023
Completion date
September 30, 2024
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, not otherwise specified